Table 1_Sex-based heterogeneity in response to first-line immunotherapy plus chemotherapy

Kai Yang published a meta-analysis on 2026-03-18, aggregating data from nine phase 3 randomized controlled trials. The dataset includes results for 5,364 patients (4,591 men and 773 women) with advanced esophageal squamous-cell carcinoma, comparing first-line immunotherapy plus chemotherapy to chemotherapy alone. It reports pooled hazard ratios for overall survival and progression-free survival, stratified by sex and PD-L1 status.

Use Cases

• Assessing sex-based heterogeneity in treatment response based on hazard ratios for overall survival and progression-free survival.
• Meta-analysis of immunotherapy efficacy in specific patient subgroups, such as the PD-L1-positive population.
• Validating the consistency of treatment benefits across sexes using statistical interaction tests and I² statistics.

Strengths

• Data is derived from nine phase 3 randomized controlled trials, a high-quality study design.
• Includes results for a specific population of 5,364 patients with advanced esophageal squamous-cell carcinoma.
• Reports specific statistical metrics, including hazard ratios with 95% confidence intervals and I² values for heterogeneity.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (13.6 KB), indicating limited scope, likely containing summary statistics rather than patient-level data.

Provenance

Source

Kai Yang via figshare.

Collection Method

Systematic review and meta-analysis of randomized controlled trials retrieved from PubMed, Web of Science, Cochrane Library, and Embase.

Time Range

Trials searched from database inception to December 1st, 2025.

Freshness

Last updated 2026-03-18 07:39:43; freshness should be verified.